The United States Food and Drug Administration (FDA) recognizes the following drugs as being affected by the CYP2C9 and/or VKORC1 genes.
  • Talk to your doctor or request an appointment with a CPMC genetic counselor to discuss the impact of your personal genetic results on your use of the following drugs.
  • Genes can have different effects on different drugs. Any interpretation or recommendations regarding increases, decreases or changes in drug dosing only apply to the drug specified.
  • There may be other drugs affected by CYP2C9 or VKORC1 that have not been recognized by the FDA at the time that this list was created or last updated.
  • There may be other genes, in addition to CYP2C9 or VKORC1 that also influence the metabolism of the drugs listed below.
  • DO NOT MAKE ANY CHANGES TO ANY MEDICATION YOU ARE TAKING WITHOUT TALKING TO YOUR HEALTH CARE PROVIDER.
Brand Name (Click on name to link to drug label) Generic Name Treatment Area Gene Involved FDA Label Recommendation
Athrombin, Coumadin, Jantoven, Panwarfarin Warfarin Hematology
(used to prevent blood clots)
CYP2C9
and
VKORC1
Specific dosage recommendations based on CYP2C9 and VKORC1 results can be found in Table 5 of the FDA label.
Celebrex Celecoxib Analgesics
(used for pain relief)
CYP2C9 Consider starting treatment at half the lowest recommended dose in CYP2C9 poor metabolizers (i.e. CYP2C9 *3/*3).
Ansaid, Flurbiprofen Flurbiprofen sodium, Ocufen Flurbiprofen Rheumatology
(used for pain relief)
CYP2C9 No specific recommendation for action based on CYP2C9 genotype is given in the drug label.
Created 6/5/12